google-site-verification: googlec7193c3de77668c9.html

Tirzepatide noninferior to dulaglutide for CV outcomes in type 2 diabetes

[
Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic CV disease, according to a study published in the Dec. 18/25 issue of the New England Journal of Medicine.


Source link

Advertisements
Views: 0

See also  Do collagen, omega-3 and whey supplements boost bone health?

Check Also

1 in 4 births in England now by emergency C-section

A quarter of all babies in England are now delivered by emergency caesarean operations, BBC …

Safe firearm storage may reduce pediatric lead exposure in households with guns

[ In homes with guns, proper storage is important in preventing injuries and deaths. Now, …

Poll finds broad support for stricter regulations on ultra-processed foods

[ Top food researchers have teamed up on a special issue of the American Journal …

Leave a Reply

Available for Amazon Prime
Lexonads | free ad network | automated website traffic.